12:12 PM EDT, 08/27/2025 (MT Newswires) -- Veracyte ( VCYT ) and University College London said that their data show Veracyte's ( VCYT ) Decipher test can help identify which prostate cancer patients might benefit from stronger chemotherapy treatment.

The Decipher Prostate Genomic Classifier also predicts which patients are unlikely to benefit from treatment intensification, helping them avoid unnecessary side effects, Veracyte ( VCYT ) and University College London said Wednesday in a statement.

Findings from a late-stage trial showed that a gene expression test can assist clinicians in personalizing chemotherapy decisions for patients, according to the statement.

Veracyte ( VCYT ) shares fell 2.2% in Wednesday trading.

Price: 28.44, Change: -0.63, Percent Change: -2.17